Roberto Bel's most recent trade in Inhibikase Therapeutics Inc was a trade of 108,176 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 108,176 | 108,176 | - | - | Stock Option (Right to Buy) | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 31 Mar 2025 | 1,173 | 22,649 (0%) | 0% | 50 | 58,650 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Sale of securities on an exchange or to another person at price $ 48.57 per share. | 24 Mar 2025 | 1,173 | 23,822 (0%) | 0% | 48.6 | 56,974 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Sale of securities on an exchange or to another person at price $ 48.58 per share. | 24 Mar 2025 | 1,173 | 24,995 (0%) | 0% | 48.6 | 56,990 | Common Stock |
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 116,585 | 116,585 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 73,580 | 73,580 | - | - | Stock Option (Right to Buy) | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 46.61 per share. | 06 Nov 2024 | 4,921 | 26,168 (0%) | 0% | 46.6 | 229,368 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 2,411 | 2,411 | - | - | Phantom Stock | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 1,976 | 4,330 | - | - | Phantom Stock | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 06 Nov 2024 | 57 | 2,354 | - | - | Phantom Stock | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 06 Nov 2024 | 47 | 4,283 | - | - | Phantom Stock | |
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 21 Oct 2024 | 1,460,000 | 1,460,000 | - | 1.4 | 2,000,200 | Common Stock |
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.61 per share. | 15 Oct 2024 | 1,581 | 21,247 (0%) | 0% | 46.6 | 73,690 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.61 per share. | 15 Oct 2024 | 953 | 22,502 (0%) | 0% | 46.6 | 44,419 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.61 per share. | 15 Oct 2024 | 901 | 23,383 (0%) | 0% | 46.6 | 41,996 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.61 per share. | 15 Oct 2024 | 527 | 24,148 (0%) | 0% | 46.6 | 24,563 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 42.55 per share. | 15 Nov 2023 | 5,584 | 21,727 (0%) | 0% | 42.5 | 237,599 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 42.55 per share. | 15 Nov 2023 | 2,873 | 24,600 (0%) | 0% | 42.5 | 122,246 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 42.55 per share. | 15 Nov 2023 | 2,714 | 25,899 (0%) | 0% | 42.6 | 115,481 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 15 Nov 2023 | 1,415 | 23,185 (0%) | 0% | 42.5 | 60,208 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 15 Nov 2023 | 1,337 | 24,562 (0%) | 0% | 42.5 | 56,889 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.05 per share. | 15 Oct 2023 | 866 | 16,143 (0%) | 0% | 42.0 | 36,415 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.05 per share. | 15 Oct 2023 | 594 | 17,379 (0%) | 0% | 42.1 | 24,978 | Common Stock |
| New Jersey Resources Corpo... | Roberto F. Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.05 per share. | 15 Oct 2023 | 507 | 16,944 (0%) | 0% | 42.0 | 21,319 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 46.00 per share. | 09 Nov 2022 | 5,079 | 17,849 (0%) | 0% | 46 | 233,634 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 43.89 per share. | 09 Nov 2022 | 1,256 | 13,389 (0%) | 0% | 43.9 | 55,126 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Grant, award, or other acquisition of securities at price $ 43.92 per share. | 09 Nov 2022 | 1,082 | 12,666 (0%) | 0% | 43.9 | 47,521 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 09 Nov 2022 | 619 | 12,770 (0%) | 0% | 43.9 | 27,186 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 09 Nov 2022 | 533 | 12,133 (0%) | 0% | 43.9 | 23,409 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.48 per share. | 15 Oct 2022 | 571 | 12,040 (0%) | 0% | 39.5 | 22,543 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.48 per share. | 15 Oct 2022 | 487 | 11,584 (0%) | 0% | 39.5 | 19,227 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.48 per share. | 15 Oct 2022 | 339 | 12,534 (0%) | 0% | 39.5 | 13,384 | Common Stock |
| New Jersey Resources Corpo... | Roberto Bel | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.17 per share. | 01 Apr 2022 | 1,172 | 12,802 (0%) | 0% | 47.2 | 55,283 | Common Stock |